Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS35A extension trial of degarelix versus goserelin in prostate cancer
NL-OMON34559Phase 3Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of degarelix and goserelin in prostate cancer (PCa) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Hazard ratio of PSA progression-free survival failure rates during 3 years of treatment between degarelix and goserelin. Started Dec 2010; status: active, not recruiting.
02
Drugs
degarelixgoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON34559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34559.